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Abstract 
Background: Lower muscle strength in midlife predicts disability and mortality in later life. 
Blood-borne factors, including growth differentiation factor 11 (GDF11), have been linked to 
muscle regeneration in animal models. We aimed to identify gene transcripts associated with 
muscle strength in adults. 
Methods: Meta-analysis of whole blood gene expression (overall 17,534 unique genes 
measured by microarray) and hand-grip strength in four independent cohorts (n=7,781, ages: 
20-104 years, weighted mean=56), adjusted for age, sex, height, weight, and leukocyte 
subtypes. Separate analyses were performed in subsets (older/younger than 60, male/female).  
Results: Expression levels of 221 genes were associated with strength after adjustment for 
cofactors and for multiple statistical testing, including ALAS2 (rate limiting enzyme in heme 
synthesis), PRF1 (perforin, a cytotoxic protein associated with inflammation), IGF1R and 
IGF2BP2 (both insulin like growth factor related). We identified statistical enrichment for 
hemoglobin biosynthesis, innate immune activation and the stress response. Ten genes were 
only associated in younger individuals, four in males only and one in females only. For example 
PIK3R2 (a negative regulator of PI3K/AKT growth pathway) was negatively associated with 
muscle strength in younger (<60 years) individuals but not older (>=60 years). We also show 
that 115 genes (52%) have not previously been linked to muscle in NCBI PubMed abstracts 
Conclusions: This first large-scale transcriptome study of muscle strength in human adults 
confirmed associations with known pathways and provides new evidence for over half of the 
genes identified. There may be age and sex specific gene expression signatures in blood for 
muscle strength.   
 
Introduction 
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Muscle strength correlates with health and physical function, and poor muscle strength in 
midlife is a strong, independent predictor of health status decline and mortality over 25 years 
(40). Sufficient muscle strength in the hands, arms and legs is needed for everyday functioning; 
persons with poor strength are at high risk of disability, injury from falls, and other age-related 
morbidities (15, 25).  
Hand-grip is a frequently used summary measure of strength because it correlates well with 
strength of other key muscles and is relatively easy to measure with high precision; Bohannon 
et al. reported strong correlations between grip and knee extension strength (Pearson R=0.77 
to 0.8) in a sample aged 18 to 85 years (7), with Samson et al. reporting similar estimates (43). 
Muscle strength (including grip strength) is a more important predictor of mortality risk than 
muscle mass (9, 32), and grip strength (but not muscle mass) was associated with poor 
physical functioning in older adults (51). The mechanisms underlying the association between 
lower strength and mortality are not entirely clear, but a recent large-scale multi-country follow-
up study (n=142,861) reported that lower grip strength associated most strongly with 
cardiovascular mortality (28). Current theories emphasize the role of denervation not 
compensated by adequate re-innervation, mitochondrial dysfunction, cellular senescence, 
inflammation, changes in microenvironment, and local skeletal changes, among other factors 
(4, 44).  
Studies of heterochronic parabiosis (connecting the blood circulations of young and old mice) 
found that circulating factors, in particular lower GDF11 (growth and differentiation factor 11) 
in older mice, explained the lower muscle regenerative capacity in older compared to younger 
muscle (8, 11, 48). It is well established that circulating factors, such as pro-inflammatory 
mediators and hormones (including testosterone), are strong correlates which predict the slope 
of decline of muscle mass and strength in aging humans (26). These blood borne factors may 
function as systemic regulators influencing muscle and may be different from gene expression 
patterns in muscle itself.  
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Previous studies of transcriptome associations with muscle strength in humans were 
conducted predominantly in muscle tissue, and are mostly limited by small sample size (30) or 
focus on candidate genes (34). These studies can be susceptible to false negatives statistical 
associations due to lack of power or coverage. A transcriptome-wide study of whole blood 
transcript associations with grip strength conducted by the InCHIANTI Aging Study (mean age 
72 years, 71% ≥72 years old) found only one gene, CEBPB (CCAAT/enhancer-binding protein 
beta, required for macrophage-mediated muscle repair in a murine model (42)), to be 
associated with muscle strength in older humans after adjustment for confounders and multiple 
testing (18). A follow-up study in humans found that CEBPB expression increased following 
exercise-induced muscle damage (6). However, because of the limited sample size of both 
studies, important transcriptional signals may have been missed.  
In the present study we sought to test associations between transcripts expressed in whole 
blood and hand grip strength in multiple adult human cohorts. The majority of RNA in whole 
blood samples is derived from immature erythrocytes and platelets (~70% from reticulocytes 
and ~18% from reticulated platelets); however, these are predominantly globin-related and are 
not actively transcribed by circulating cells (1). The remaining  approximately 12% of RNA is 
from circulating white blood cells of all types, driving non-globin related gene expression. We 
have also performed subgroup analyses by age-group and gender, to check for heterogeneity 
in the results. We used a robust meta-analysis framework within four independent cohorts 
(n=7,781 participants) from the CHARGE (Cohorts for Heart and Aging Research in Genomic 
Epidemiology) consortium (37) to identify the genes whose levels of expression assessed by 
blood transcripts were associated with muscle strength.  
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Methods 
Study sample 
Characteristics of the cohorts are presented in Table 1. Complete data for the planned meta-
analysis were available for 7,781 participants from four cohorts; the Framingham Heart Study 
(23) (FHS, n=5,576, ages=24-90), the InCHIANTI study (13) (n=667, ages=30-104), the 
Rotterdam study (20) (RS, n=556, ages=46-89) and the Study of Health in Pomerania (52) 
(SHIP, n=982, ages=20-81) (total n=7,781). The FHS study included two related generations 
of participants (accounted for in the statistical methodology); the FHS Generation 2 (n=2,421, 
ages=40-90) and Generation 3 (n=3,155, ages=24-78) cohorts were included. The 
Netherlands Study of Depression and Anxiety (35) (NESDA, n=1,989, ages=18-65) is also 
reported, but was not included in the discovery meta-analysis due to unavailable data on white 
cell proportions necessary for the meta-analysis protocol. Overall the cohorts were quite similar 
with respect to sex-distribution and sampling methods, differing only by age distribution and 
lower mean hand-grip strength in the RS. Detailed study design and cohort information has 
been previously published (21). 
Four additional subset analyses were performed. The sub-samples available were 1) older 
participants ≥60 years (n=2,402), 2) younger participants <60 years (n=5,379), 3) male 
participants (n=3,557), 4) female participants (n=4,224).  
 
Phenotype 
The primary phenotype was hand-grip strength in kg (a normally distributed phenotype). In the 
FHS, hand grip strength was measured with a Jamar dynamometer with three trials performed 
in each hand, and the maximum of the six trials for each participant was used in the analysis. 
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In InCHIANTI each participant recorded their maximum grip strength three times in each hand, 
and the maximum recorded value of the six trials was used. In the Rotterdam Study grip 
strength of the non-dominant hand was measured three times for each participant, and the 
maximum recorded value was used. In the SHIP cohort participants were asked to press the 
hand dynamometer firmly for several seconds, once per hand (left and right), and the maximum 
value was used. Each participant in NESDA was measured twice with a Jamar dynamometer 
in their dominant hand, with the maximum recorded value used. 
 
Peripheral gene expression data 
Blood samples were drawn from participants and RNA was isolated, reverse-transcribed to 
cDNA, which was then amplified and hybridized to a microarray individually for each cohort; 
methods described in detail (21). Briefly, the FHS used Affymetrix Human Exon 1.0 ST 
GeneChips, characterizing the expression of 16,798 unique genes (after exclusion of 
probesets with relative log expression mean values <3). The InCHIANTI and SHIP studies 
used the Illumina HumanHT-12 v3 Expression BeadChip Kit, and the RS used the Illumina 
HumanHT-12 v4 Expression BeadChip Kit, with 37,348 probes measured on both Illumina 
platforms (22,911 unique genes; after exclusions of probes expressed above background in 
<5% of participants this becomes 15,639 unique genes). These four studies in the primary 
analysis all used PAXgene tubes to isolate and stabilize the RNA, thereby limiting the technical 
variability between studies. Finally the NESDA cohort utilized the Affymetrix Human Genome 
U219 Array, with expression information available on 18,212 unique gene identifiers. Quantile 
normalization and log2 transformation was performed on the gene expression data in each 
cohort, and both probes and samples were z-transformed. Raw data from gene expression 
profiling are available online (FHS [NCBI dbGAP: phs000363.v7.p8], InCHIANTI [GEO: 
GSE48152], NESDA [NCBI dbGAP: phs000486.v1.p1], RS [GEO: GSE33828] and SHIP-
TREND [GEO: GSE36382]). 
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Systematically mapping pairs of probes to RefSeq transcripts (one Affymetrix Exon ST and 
one Illumina HumanHT-12 probe) found 26,746 probe-pairs corresponding to 17,534 unique 
RefSeq gene symbols. The assignment of a probe to one or more transcripts was performed 
as described previously (45). For the Illumina arrays, the transcript sequences derived from 
the 48,803 probe sequences provided in the Illumina annotation file (HumanHT-
12_V3_0_R3_11283641_A, version 3.0, 7/1/2010) were mapped against all available mRNA 
sequences provided in the UCSC genome annotation database (version 06/30/2013) using 
string matching. Altogether 29,818 probes were successfully mapped to one or more validated 
mRNAs. Probes that could neither be mapped to a unique mRNA nor to a single annotated 
RefSeq gene using the UCSC database were flagged accordingly in the annotation file. In total, 
27,171 probes (55.7%) were unambiguously associated with a single mRNA or gene. The 
same method and version of the UCSC database was used for mapping the probes of the 
Affymetrix GeneChip Human Exon 1.0 ST microarray. For this array, probe sequences were 
obtained from the annotation file version HuEx-1_0-st-v2.r2 restricting the probes to the main 
probe types of the core dataset with unique cross hybridization type, and combining them at 
the level of transcript cluster. For this array system, 196,515 probes (86.0%) of 17,876 
transcript clusters were unambiguously associated with a single mRNA or gene. Finally, the 
probes of both array systems were combined based on the same transcripts obtained from the 
mapping against the UCSC database.  
The Human Genome Nomenclature Committee (22) list 19,060 protein-coding genes (Sept 15, 
2014), less than the total “unique identifiers” mapped by the two arrays used in the overall 
meta-analysis; this discrepancy is due to probes on the array mapping to non-protein-coding 
transcripts, which we have included under the term “unique genes” or “transcripts” in this 
manuscript. 
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Statistical analysis 
Using the R statistical software (39) and package “lme4” (3) each cohort performed a linear 
mixed effects model for each probe in their microarray data, using the probe as the outcome, 
muscle strength as an independent variable, and with the following covariates included as fixed 
effects; age, sex, height (cm), weight (kg), cell count estimates (neutrophils, monocytes, 
basophils and eosinophils), and fasting state (where applicable). By including these factors as 
covariates in the models our results are independent of inter-individual variation in, for 
example, lymphocyte cell counts. The following covariates were included as random effects; 
batch (e.g. amplification and/or hybridization), study site (in InCHIANTI), family structure (in 
FHS), and RNA quality (e.g. RNA Integrity Number - RIN - where available). Empirical cell 
counts were only available in half of the FHS cohort; the rest of the cohort was imputed using 
partial least square regression methods (see Online Methods for more details). 
 
Meta-analysis 
A sample-size weighted meta-analysis method was used, where an overall p-value and Z-
score for each probe are calculated which together describe the significance of the effect, and 
the direction and magnitude, respectively; this method was chosen over the effect 
size/standard error method because of the multiple array technologies and technical 
considerations that differed between the cohorts. The analysis was done using the Meta-
Analysis Tool for Genome Wide-Association Scans (METAL) (54) which took the effect size, 
sample size, and p-values from the individual cohort results as input (we set the “minor allele”, 
“major allele”, “minor allele frequency”, and “strand” to the same fixed value for all cohorts and 
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probes, as this package was developed for GWAS and these options are not relevant for gene 
expression data). 
For each analysis (the primary analysis including all individuals, and the four subset analyses) 
the Illumina-based cohorts (InCHIANTI, RS, SHIP) were meta-analyzed together, as these 
technologies are very similar, then a secondary meta-analysis was performed which used the 
FHS results and the Illumina results as the input; these are the final meta-analysis results 
reported. This reduced the heterogeneity in the meta-analysis due to array differences 
between the cohorts. 
Before interpretation of the results, probes were excluded if they were expressed in <5% of 
the sample or if the heterogeneity p-value calculated by METAL was <0.05. The Benjamini-
Hochberg (BH) (5) false-discovery rate (FDR) correction was applied to determine the 
statistically significant probes for each analysis. Validation was defined as a gene with p<0.05 
in the NESDA cohort. 
 
Ontology enrichment and network analysis 
The WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) online resource is a method for 
determining pathway enrichment (56). We conducted a “Gene Ontology” analysis (database 
version: Nov 11, 2012) and a “Human Phenotype Ontology” analysis (database version: May 
20, 2014), which uses a systematic approach to phenotype abnormalities to link them into 
ontologies (53). Default analysis options were selected, including BH multiple testing 
adjustment, and the list of 17,534 genes included in the meta-analysis we used as the 
“background”. 
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A co-expression analysis was performed in the FHS (as the study with the largest sample size) 
where Spearman correlations were determined between each gene significantly associated 
with muscle strength, and all other genes (after adjusting the data for the covariates mentioned 
in the Statistical Analysis methods section). Genes correlated with rho ≥ 0.5 were selected for 
visualization in Cytoscape (v3.2.1). Ontology enrichment of networks was performed in 
Cytoscape using the BiNGO plugin (v2.44). 
 
A priori genes associated with muscle function 
We selected sets of genes known to influence muscle function for a priori analysis to highlight 
whether the pathways in muscle tissue are also important in whole blood. Kelch proteins, 
including KLHL19, KLHL31, KLHL39m, and KLHDC1, are involved in skeletal muscle function 
and development [8]; canonical and non-canonical Wnt signaling play crucial roles in 
maintenance and development of skeletal muscle [7]; insulin-like growth factors (IGF’s) are 
also known to play roles in muscle growth and homeostasis [9], and finally TGF-β family 
members, including myostatin (GDF8) (27) and GDF11. Supplementation of GDF11 in mice 
was reported to ameliorate the sarcopenia-like phenotype [15]. In their 2007 study, Melov et al 
identified 586 unique genes expressed in muscle that were associated with endurance 
exercise training and differed between older and younger men (30), which we also checked 
for associations with muscle strength in this analysis. 
 
Systematic literature search for genes 
For each significant gene in the analysis a systematic search of literature was performed by 
accessing the “publications” list from GeneCards (www.genecards.org) (41), which has the 
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advantage of including publications where the gene ID may have changed over time. From this 
list the title and abstract were downloaded from NCBI PubMed 
(www.ncbi.nlm.nih.gov/pubmed). Searches were then made within each publication for the text 
string “muscle”, and results counted. 
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Results 
Meta-analysis: genes associated with muscle strength 
Overall, 26,746 probe-pairs (corresponding probes on the Affymetrix and Illumina platforms), 
mapping to 17,534 unique gene identifiers, were available for the meta-analysis. Including data 
from all 7,781 participants, 208 unique genes (246 probe-pairs) were associated with muscle 
strength (FDR<0.05; Figure 1; see Supplementary Table 1 for all significant results) after 
correction for multiple confounders, and excluding results with significant heterogeneity (het 
p<0.05) between cohorts; 133 were negatively associated with grip strength, 75 were positively 
associated.  
Of the 208 unique genes associated with muscle strength in the meta-analysis all were 
significant in FHS alone (nominal p<0.05), and 79 (38%) were also “independently” associated 
with muscle strength in the Illumina meta-analysis (nominally significant; p<0.05). Details of 
the statistically most significant ‘top’ 20 transcripts are shown in Table 2. The proportion 
“independently replicated” was greater for the top 30 most significant genes identified in the 
meta-analysis (21 of 30 = 70%).  
 
Meta-analysis in subsets of the participants 
The analyses in subsets of the participants identified 13 genes associated with muscle strength 
at transcriptome-wide significance in the meta-analysis that were not identified in the analysis 
of all participants together (Table 3; see Supplementary Table 2-4 for full results for each 
subset). We also investigated whether the 208 genes identified in the analysis of all individuals 
were nominally significant (p<0.05) in the subsets. 153 of the 208 genes were nominally 
significant in the older participants, 198 in the younger, 200 in the males and 121 in the females 
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(Supplementary Table 1). Supplementary Table 5 includes additional information for all 
genes included in Tables 2 & 3. 
 
Significant genes only available on one array 
Due to differences between the array technologies and relative abundance of transcripts, not 
all the genes were eligible for the meta-analysis. In the analysis on all individuals, 1,123 probes 
(898 unique identifiers) were present on the Affymetrix Exon array that did not have a 
corresponding probe on the Illumina array; 21 of these probes were significantly associated 
with hand-grip strength after BH adjustment for multiple testing (see Table 4 for top 20 probes 
in the “all individuals” analysis and Supplementary Tables 6-8 for list of significant probes in 
each of the FHS analyses with significant results).  In the Illumina array, 7,768 probes (6,119 
unique gene identifiers) were available that did not map to a gene/transcript in the Affymetrix 
Exon array (after excluding lowly expressed probes). None of the probes were significantly 
associated with muscle strength after BH multiple testing correction. 
 
Ontology enrichment of strength-associated genes 
Two analyses were performed to identify pathways using the WebGestalt web resource based 
on the 208 genes associated with muscle strength in the meta-analysis of all participants; 
1. Gene Ontology analysis found that 10 biological processes were significantly enriched 
(FDR<0.05) (Table 5) including “hemoglobin metabolic process” and related processes, 
“innate immune response” (18 genes) and the stress response (55 genes); 10 molecular 
functions were enriched (including “protein binding genes”), and 10 cellular component 
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pathways were enriched (including “intracellular membrane-bound organelle”) (See 
Supplementary Table 9).  
2. Human Phenotype Ontology analysis found 10 phenotypes significantly enriched in the 
genes, including “Anemia due to reduced life span of red cells”, “Hemolytic Anemia”, and 
“Abnormality of erythrocytes” (See Supplementary Table 10). 
Additionally, network analysis in the FHS of all genes correlated (rho ≥ 0.5) with the strength-
associated genes (n=425) revealed four clusters with at least 10 genes, all of which had a 
number of significantly (FDR p<0.05) enriched pathways (Supplementary Table 11): 1) the 
largest cluster (n=333 of 425 genes) included “protein ubiquitination”, “erythrocyte 
homeostasis”, and “cellular metabolic process”. 2) The second cluster (n=32 genes) was 
enriched for genes in “regulation of cell communication”, “actin cytoskeleton” and “ATP 
metabolic process”. 3) The third cluster (n=18) had two enriched ontologies only: “cell surface 
receptor-linked signaling pathway” and “cytolysis”. 4) The final cluster (n=10) was enriched for 
terms including “negative regulator or immune system process” and “negative regulation of 
complement activation”. 
 
A priori genes associated with muscle function 
Of 20 IGF-related genes tested in this meta-analysis two were significantly associated with 
muscle strength: IGF1R (positively associated) and IGF2BP2 (negatively associated; meta-
analysis FDR=3.2x10-2 and FDR=1.2x10-3, respectively). Expression of myostation (MSTN), 
follistatin (FST) and GDF11 were not associated with muscle strength (FDR>0.05). 40 unique 
Kelch genes were tested in the meta-analysis; none were associated with muscle strength in 
whole blood (FDR>0.05). 18 unique Wnt genes (from WNT1 to WNT9B) were tested in the 
meta-analysis; none were associated with muscle strength in whole blood (FDR>0.05). All 10 
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Frizzled genes (FZD1-10, receptors for the Wnt pathway) were also available to test; none 
were associated with muscle strength. Similarly all three Dishevelled genes were available to 
test (DVL1-3, acts directly downstream of the Frizzled receptors) and none were associated 
with muscle strength. Of 586 genes identified by Melov et al that were differentially expressed 
in muscle tissue between old and young men following endurance training (30) four were 
associated with muscle strength in this analysis: ANP32B, CIRBP, MCM7 and MGST1. 
 
 
Most associated genes are not previously linked to muscle in the literature 
For each of the 221 genes associated with muscle strength we searched in the published 
literature cataloged on GeneCards and NCBI Pubmed titles and abstracts, using the search 
term “muscle”: for 115 of these 221 genes (52%) there were no mentions of muscle (as of Nov 
12, 2014; Supplementary Table 12). 
 
Few genes replicate in the NESDA cohort 
NESDA was not included in the meta-analysis due to data limitations: the lack of empirically 
determined or reliably imputed white cell count data, the use of a different microarray 
technology (a predecessor to the Exon array used by FHS, much more dissimilar than the 
v3/v4 Illumina arrays are to one another), and a younger population than the other cohorts 
included in the meta-analysis (max age=65, see Table 1). 
As noted above, in total 221 unique genes were associated with muscle strength across all the 
meta-analyses performed. Of 208 genes significantly associated with muscle strength in 
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analysis 1 (all participants) it was possible to test 144 in the NESDA cohort; 7 genes were also 
associated with muscle strength (p<0.05) in the NESDA cohort (ACSL6, ALDH5A1, 
CARHSP1, FGL1, NRG1, PIGB, SIGLEC7).  
 
Associations with knee strength 
Maximum knee and grip strength (both in Kg) were measured in 619 participants in the 
InCHIANTI study and were highly correlated (Pearson R=0.751), and were significantly 
associated after adjustment for age, sex, height and weight (coefficient=0.193, p=8.2x10-15) in 
linear regression models with knee strength as the dependent variable. 
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Discussion 
In this discovery study we set out to determine whether specific transcript levels in blood are 
associated with muscle strength in multiple human cohorts including mostly middle-aged 
volunteers. Previous cross-sectional (and longitudinal) studies have shown that the degree 
and rate of loss of strength (and muscle mass) is greater in older participants (31). We 
therefore performed stratified analyses by age and gender to determine whether transcripts or 
pathways associated with muscle strength in whole blood differ between these groups. 208 
unique genes were associated with muscle strength in the analysis of all participants (Table 2 
for 20 most robust associations). Thirteen additional unique genes were identified that were 
only associated when participants were separated into older/younger or male/female groups 
(Table 3). In total 221 unique genes were associated with muscle strength in at least one 
analysis, 52% of which were not previously linked to the term “muscle” in the published 
literature cataloged on GeneCards and PubMed (as of Nov 12, 2014). 
We observe significant associations between muscle strength and expression of IGF1R and 
IGF2BP2 (positive and negative directions of association with muscle, respectively), growth 
factors involved in skeletal muscle growth (33, 46); the former is known to enhance cell survival 
by mediating IGF1 signaling, and the latter modulates IGF2 translation and has genetic 
variants associated with type-2 diabetes (19). Of 586 genes that differ in expression in muscle 
between old and young men after endurance training (30), four were associated with grip 
strength in this study: MGST1 (negative direction), an immune mediator which may protect 
against oxidative stress (49); MCM7 (positive direction), which regulates DNA replication 
during proliferation (12); CIRBP (positive direction), which promotes inflammation in response 
to shock and sepsis (38); and ANP32B (negative direction), a cell-cycle progression and anti-
apoptosis factor (41). These latter results suggest that most blood based gene expression 
associated with strength is different from that seen in muscle itself, which is not unexpected 
given the respective systemic regulatory versus myofibril maintenance functions involved. 
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Further work should explore whether transcripts that alter in response to exercise show 
overlaps between circulating cells and muscle. Interestingly, no genes from the Wnt or Kelch 
pathways (both known to be important for muscle function (14, 29)) were associated with 
strength in this analysis; nor was GDF11, a protein that can reverse age-related muscle 
dysfunction in mice (48), although as noted we observe associations between strength and 
expression of two IGF-related genes. 
Other genes of note include CCR6 and PRF1 (both positively associated with muscle strength 
and age (17)): CCR6 is implicated in B-cell maturation and recruitment (36); perforin (PRF1) 
is a protein secreted by cytotoxic T-cells which creates pores in membranes to permit 
apoptosis-inducing granzyme into the target cell (50). These findings are consistent with the 
notion that inflammation may be associated with muscle repair, maintenance and turnover, at 
least in part by interfering with the production and biological activity of IGF-1 (2). 
NANOG expression was measured in the FHS analysis only and is positively associated with 
strength in the FHS analysis (Table 4); NANOG can reverse aging of some stem cells (16) 
and, in combination with three other genes (OCT4, SOX2, and LIN28, not significant in this 
analysis), can induce pluripotency of somatic cells (55). This may suggest that differentiation 
(of whole blood cells) is inversely correlated with muscle strength, but the mechanisms are 
unclear. 
 
Genes identified in subset analyses 
Thirteen genes were associated with muscle strength at transcriptome-wide significance in the 
subset analysis only (Table 3). These were predominantly in the younger (<60 years) group 
and included PIK3R2, a negative regulator of the PI3K/AKT growth pathway; the negative 
expression association with strength suggests that there is increased PI3K activity (due to 
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reduced expression of PIK3R2) with increasing muscle strength, in whole blood. This 
association is observed in the younger subset (p=6x10-5) but not in the older subset, even 
nominally (p=0.92), suggesting differences in growth pathway expression in blood with respect 
to muscle strength as individuals age. Similarly expression of PDK4 (inhibits pyruvate 
dehydrogenase in mitochondria, thereby reducing the conversion of pyruvate into acetyl-CoA) 
is negatively associated with strength, suggesting increased pyruvate dehydrogenase activity 
with increased strength in younger individuals only. PKN2, (associated with height (19) and 
cell-cycle progression), is positively associated with strength in the younger individuals, 
underlining the difference in growth pathways in whole blood between younger and older 
individuals. See Supplementary Table 5 for more details on the other results. 
Defensin, Alpha 4, Corticostatin (DEFA4, negative strength association in the analysis of 
females only) is a cytotoxic peptide that has antimicrobial activity against Gram-negative 
bacteria (predominantly) (36). In males, expression of RAC1 (membrane-associated GTPase 
involved in signal transduction, including growth signals) and NDUFS1 (member of 
mitochondrial complex 1, may form part of the active site) were positively associated with 
muscle strength; these associations may suggest that on average males have specific energy 
and growth-related gene expression relating to strength. 
No genes were associated (transcriptome-wide) in the older participants only; although the 
sample size was still reasonably high (2,402 participants), variability in the strength phenotype 
as individuals age and development of various co-morbidities plus chronic inflammation may 
reduce the power to detect associations. Subset-specific gene-expression associations with 
strength reported here need to be replicated and added to, as we may lack statistical power in 
this study to detect smaller-effect associations, and the microarrays do not quantify all 
transcripts or isoforms present. 
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Enrichment analysis 
WebGestalt analyses identified statistically significant enrichment for genes in the biological 
process “Hemoglobin Metabolic Process” and the phenotypic abnormality “Hemolytic Anemia”, 
amongst others. Anemia is a cross-sectional correlate of muscle strength and predicts 
accelerated muscle strength decline with aging (10), while hemoglobin levels are positively 
associated with muscle strength and density (10). Circulating reticulocytes (erythrocyte 
precursors with some residual RNA present) were not adjusted for in this analysis and are 
likely the source of the associations with genes such as ALAS2 (strongest meta-analysis 
association, negative direction - a rate-limiting step in heme biosynthesis (24)).  
“Innate Immune Response” - which includes macrophages - genes were also enriched in the 
results. CEBPB, the gene implicated in the macrophage wound-healing response (42) and 
significantly associated with muscle strength in the 2012 study by InCHIANTI (18), did not 
replicate in the other cohorts. This could be due to methodological differences between the 
previous study and this meta-analysis, as well as differences in age distribution (81% of the 
InCHIANTI cohort is aged >=60 years, compared to 31% in this analysis, which includes the 
InCHIANTI cohort; Table 1). The implications are unclear given the mouse model evidence of 
plausible biological mechanism (42) and evidence in humans that exercise-induced muscle 
damage is associated with CEBPB expression changes in whole blood (6). Further work is 
required in older and frail groups. 
Co-expression analysis of all genes correlated with those identified in the meta-analysis to be 
significantly associated with strength revealed four clusters. Ontology enrichment analysis of 
these revealed very similar results to those identified using WebGestalt only on the genes 
significantly associated with strength, emphasizing the association of immune activation and 
cell signaling pathways to muscle strength in whole blood, in addition to hemoglobin pathways. 
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Limitations  
There are several potential limitations of this study including its cross-sectional design; it is not 
possible to determine a causal direction in this study for the associations reported, but the 
robustly identified markers emerging provide a sound foundation for follow-up studies to 
address causation. Grip strength is strongly correlated with strength in other key muscle 
systems (see introduction), but further work will be needed to confirm more specific gene 
expression associations with strength in other muscle groups. Grip strength can be influenced 
by non-muscle strength factors, including functional anomalies in the hands, for example 
caused by Rheumatoid Arthritis (47), and work is needed to clarify whether any of our findings 
reflect these alternative influences.  
Another potential limitation is the mixed cell subtype composition of “whole blood”: our analysis 
approach based on overall expression should have greater power to detect net expression 
changes in common immune cell types or large changes in expression of highly specific genes, 
but will have less power to detect smaller expression changes within less numerous cell 
subtypes. The cell subtype origins of the top transcripts reported here now need to be 
identified. Additionally, the microarray technology used across the participating cohorts was 
not the same. However, 21 (70%) of the top 30 meta-analysis results were independently 
replicated between the platforms, which suggests that the top (most strongly associated) 
results are very robust to cohort and array differences. Also, the current analysis has identified 
expressed genes statistically associated with muscle strength, but future work will be needed 
to identify the mechanisms underlying these associations, and whether these act on muscle 
directly or through indirect pathways, perhaps with effects on central command, cerebellar 
coordination or neural transmission. Finally, work is needed on whether the identified strength 
associated gene expression transcripts are predictive of subsequent changes in strength or 
functional decline.  
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Conclusions 
In this first large-scale transcriptome wide study in human blood, we have identified robust 
associations between the expression of 221 genes and muscle strength in adults. Several 
known pathways were confirmed, including growth factor-related genes, the innate immune 
response and hemoglobin metabolism. For 115 genes this analysis appears to provide the first 
published link to muscle. The analysis also suggests that parts of the expression signatures 
may be specific to subgroups, notably with 10 genes associated with muscle strength only in 
younger people.  
Further work is needed to establish which of the identified genes predict future changes in 
strength. The findings of genes via expression microarrays may help identify key changes in 
cell subtypes in blood contributing to strength, through studies of the cellular origins of gene 
expression signals. Future research should also include longitudinal data to assess whether 
expression of the identified genes predicts poor muscle strength or functional outcomes. 
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Table 1 | Characteristics of the study cohorts 
 
  Meta‐analysis cohorts    Additional cohort ∞ 
Variables  FHS Gen 2 *  FHS Gen 3 *  InCHIANTI ~  RS3 ~  SHIP ~     NESDA 
     
N  2,421  3,155  667  556  982    1,989 
N >= 60 years (%)  1,319 (54%)  48 (1%)  547 (81%)  264 (45%)  268 (27%)    158 (8%) 
Sex (male), n (%)  1,095 (45%)  1,470 (47%)  311 (46%)  272 (46%)  435 (44%)    1,328 (67%) 
Age (yrs), mean±SD  66 ± 8.9  46 ± 8.8  72 ± 15  60 ± 7.9  50 ± 14    42 ± 13 
Age (yrs), min:max  40 : 90  24 : 78  30 : 104  46 : 89  20 : 81    18 : 65 
WBC‐counts  yes ɫ  yes   yes  yes  yes    no 
     
Hand‐grip strength     
Mean ± SD (Kg)  31 ± 12  38 ± 12  29 ± 12  25 ± 9.4  38 ± 12    38 ± 12 
Min : max (Kg)  1 : 76  5 : 84  3 : 76  2 : 55  11 : 73    10 : 90 
     
Microarray platform 
Affymetrix 
GeneChip 
Human 
Exon 1.0 ST 
Affymetrix 
GeneChip 
Human 
Exon 1.0 ST 
Illumina 
HumanHT‐
12 v3 
BeadChip 
Illumina 
HumanHT‐
12 v4 
BeadChip 
Illumina 
HumanHT‐
12 v3 
BeadChip 
  Affymetrix Human 
Genome U219 Array 
                       
FHS=Framingham Heart Study; RS3=Rotterdam Study 3; SHIP=Study of Health in Pomerania; NESDA=Netherlands Study of 
Depression and Anxiety; SD=standard deviation; WBC=white blood cell 
* FHS cohorts analyzed together prior to overall meta‐analysis 
~ Illumina‐based cohorts analyzed together prior to overall meta‐analysis 
∞ cohort not included in meta‐analysis due to data missing from analysis protocol 
ɫ cell counts imputed in this dataset; see methods 
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Table 2 | Top 20 unique genes associated with muscle strength in the meta-analysis of all participants, with robust replication in Illumina 
 
Meta‐analysis  p‐values 
Zscore  p‐value  BH p‐value  FHS  Illumina  Gene  EntrezID  Name 
‐5.67  1.5x10‐8  2.0x10‐4  3.9x10‐7  9.9x10‐3  ALAS2  212  aminolevulinate, delta‐, synthase 2 
5.37  7.8x10‐8  3.1x10‐4  4.3x10‐7  4.0x10‐2  HEATR5A  25938  HEAT repeat containing 5A 
‐5.28  1.3x10‐7  3.9x10‐4  2.7x10‐5  1.2x10‐3  PNP  4860  purine nucleoside phosphorylase 
‐5.17  2.4x10‐7  4.7x10‐4  1.1x10‐6  5.0x10‐2  STOM  2040  stomatin 
5.14  2.8x10‐7  4.7x10‐4  7.9x10‐6  1.1x10‐2  RPS6KA5  9252  ribosomal protein S6 kinase, 90kDa, polypeptide 5 
‐5.09  3.7x10‐7  5.8x10‐4  5.4x10‐5  1.8x10‐3  MBNL3  55796  Muscleblind‐Like Splicing Regulator 3 
‐5.07  3.9x10‐7  5.8x10‐4  2.3x10‐6  4.4x10‐2  RAD23A  5886  RAD23 homolog A (S. cerevisiae) 
5.02  5.1x10‐7  6.8x10‐4  7.7x10‐5  1.7x10‐3  HNRNPA0  10949  heterogeneous nuclear ribonucleoprotein A0 
‐4.90  9.5x10‐7  1.1x10‐3  2.0x10‐5  1.5x10‐2  GID4  79018  GID Complex Subunit 4 
‐4.88  1.1x10‐6  1.1x10‐3  9.3x10‐6  3.4x10‐2  TFDP1  7027  transcription factor Dp‐1 
4.80  1.6x10‐6  1.4x10‐3  9.9x10‐6  4.7x10‐2  ARRDC3  57561  arrestin domain containing 3 
‐4.77  1.7x10‐6  1.5x10‐3  1.8x10‐5  3.3x10‐2  RIOK3  8780  RIO kinase 3 
‐4.71  2.5x10‐6  1.8x10‐3  1.9x10‐5  4.1x10‐2  NTAN1  123803  N‐terminal asparagine amidase 
4.66  3.1x10‐6  2.2x10‐3  8.1x10‐4  6.0x10‐4  PDE4D  5144  phosphodiesterase 4D, cAMP‐specific 
‐4.62  3.8x10‐6  2.4x10‐3  1.1x10‐4  1.2x10‐2  RGCC  28984  Regulator Of Cell Cycle 
4.61  4.1x10‐6  2.5x10‐3  9.6x10‐5  1.4x10‐2  POLR2B  5431  polymerase (RNA) II (DNA directed) polypeptide B 
‐4.59  4.4x10‐6  2.5x10‐3  6.1x10‐5  2.4x10‐2  EIF1B  10289  eukaryotic translation initiation factor 1B 
4.57  4.8x10‐6  2.7x10‐3  5.4x10‐4  2.0x10‐3  CIRBP  1153  cold inducible RNA binding protein 
‐4.57  4.8x10‐6  2.7x10‐3  6.2x10‐5  2.7x10‐2  ASGR2  433  asialoglycoprotein receptor 2 
‐4.55  5.3x10‐6  2.9x10‐3  3.8x10‐5  4.5x10‐2  CA1  759  carbonic anhydrase I 
BH=Benjamini‐Hochberg. Ordered by meta‐analysis p‐value. Showing top 20 results with nominal 'replication' (p<0.05) in Illumina. 
Duplicate gene entries excluded. Full table in Supplementary Table 1.  
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Table 3 | Thirteen genes associated with muscle strength in age or gender specific subset analyses 
 
Subset  Meta‐analysis of subset  p‐values   
Group  N  Zscore  P‐value  BH P‐value  FHS  Illumina  Gene  Name 
Younger & Male  5379  ‐4.879  1.1 x10‐6  9.5 x10‐3  2.4 x10‐6  1.3 x10‐1  ASAP1  ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 
Younger  5379  4.495  6.9 x10‐6  2.5 x10‐2  7.5 x10‐5  3.3 x10‐1  PKN2  protein kinase N2 
Younger  5379  ‐4.426  9.6 x10‐6  2.5 x10‐2  2.9 x10‐5  6.1 x10‐1  RNF175  ring finger protein 175 
Younger  5379  ‐4.407  1.1 x10‐5  2.5 x10‐2  3.3 x10‐5  2.4 x10‐1  TMED5  transmembrane emp24 protein transport domain containing 5 
Younger  5379  4.235  2.3 x10‐5  3.5 x10‐2  4.2 x10‐5  4.7 x10‐1  ZFYVE27  zinc finger, FYVE domain containing 27 
Younger & Male  5379  ‐4.217  2.5 x10‐5  3.5 x10‐2  3.4 x10‐3  2.5 x10‐3  GID8  GID complex subunit 8 
Younger  5379  ‐4  6.3 x10‐5  4.2 x10‐2  1.7 x10‐4  1.2 x10‐2  PIK3R2  phosphoinositide‐3‐kinase, regulatory subunit 2 
Younger  5379  ‐3.961  7.5 x10‐5  4.2 x10‐2  7.3 x10‐6  3.3 x10‐1  PDK4  pyruvate dehydrogenase kinase, isozyme 4 
Younger  5379  ‐3.961  7.5 x10‐5  4.2 x10‐2  2.0 x10‐6  6.7 x10‐1  CTNNAL1  catenin (cadherin‐associated protein), alpha‐like 1 
Younger  5379  ‐3.937  8.3 x10‐5  4.4 x10‐2  7.6 x10‐5  1.2 x10‐1  COQ9  coenzyme Q9 
Male  3557  4.565  5.0 x10‐6  1.9 x10‐2  1.2 x10‐5  1.1 x10‐1  RAC1  ras‐related C3 botulinum toxin substrate 1 
Male  3557  4.041  5.3 x10‐5  4.3 x10‐2  8.0 x10‐5  1.9 x10‐1  NDUFS1  NADH dehydrogenase (ubiquinone) Fe‐S protein 1, 75kDa ... 
Female  4224  ‐4.907  9.3 x10‐7  2.5 x10‐2  8.0 x10‐4  1.1 x10‐4  DEFA4  defensin, alpha 4, corticostatin 
BH=Benjamini‐Hochberg. Some genes were identified in in multiple groups; for these genes the statistics for the larger group are given; in all cases direction of 
association is the same. Ordered by subset, then P‐value. 
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Table 4 | Top 20 probes in the FHS analysis that did not map to a corresponding Illumina probe, ordered by p-value 
 
Estimate  P‐value  BH P‐value  Chr  Start  Gene  Name 
‐0.0037  1.76x10‐6  1.49x10‐3  1  144989319 
‐0.0028  4.89x10‐6  2.88x10‐3  9  37800563  DCAF10  DDB1 and CUL4 associated factor 10 
0.0031  8.57x10‐6  4.12x10‐3  1  150522766  ADAMTSL4  ADAMTS(a disintegrin and metalloproteinase with thrombospondin motifs)‐like 4 
0.0038  9.29x10‐6  4.15x10‐3  16  89980135 
0.0040  1.95x10‐5  5.97x10‐3  2  162412847  SLC4A10  solute carrier family 4, sodium bicarbonate transporter, member 10 
0.0029  3.24x10‐5  7.74x10‐3  16  9186734 
0.0031  3.93x10‐5  8.51x10‐3  1  44440179  ATP6V0B  ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 
‐0.0027  4.10x10‐5  8.64x10‐3  3  63819562  THOC7  THO complex 7 homolog (Drosophila) 
0.0032  5.38x10‐5  9.81x10‐3  20  3898284 
0.0019  1.49x10‐4  1.70x10‐2  20  1316212 
0.0018  1.89x10‐4  1.91x10‐2  3  128628719  ACAD9 | KIAA1257  acyl‐CoA dehydrogenase family, member 9 | KIAA1257 
‐0.0017  2.21x10‐4  2.08x10‐2  1  8021733  PARK7  parkinson protein 7 
0.0036  3.18x10‐4  2.69x10‐2  12  57809458 
0.0010  3.20x10‐4  2.70x10‐2  1  153901987  DENND4B  DENN/MADD domain containing 4B 
‐0.0019  3.56x10‐4  2.87x10‐2  3  10157370  BRK1  BRICK1, SCAR/WAVE actin‐nucleating complex subunit 
‐0.0028  3.84x10‐4  2.97x10‐2  2  95517671  TEKT4  tektin 4 
‐0.0014  3.95x10‐4  3.03x10‐2  1  247937996  OR9H1P  olfactory receptor, family 9, subfamily H, member 1 pseudogene 
0.0018  6.01x10‐4  3.89x10‐2  9  124042152  GSN‐AS1  GSN(gelsolin) antisense RNA 1 
0.0028  6.41x10‐4  4.03x10‐2  6  20451305 
‐0.0021  6.90x10‐4  4.19x10‐2  12  8024178  NANOGP1 | NANOG  Nanog homeobox pseudogene 1 | Nanog homeobox 
BH=Benjamini‐Hochberg. Blank gene symbols were not annotated to a specific gene. Table continued in Supplementary Table 9. Ordered by P‐value. Not all probes map 
to gene ID’s. 
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Table 5 | Ten biological processes were enriched in the genes associated with muscle strength in the analysis of all participants 
 
Biological Process  C  O  rawP  adjP  Top Genes 
hemoglobin metabolic process (GO:0020027)  14  5  3.2x10‐7  0.0004  ALAS2, AHSP, FECH, EIF2AK2, EPB42 
hemoglobin biosynthetic process (GO:0042541)  9  3  1.0x10‐4  0.0139  ALAS2, FECH, EIF2AK2 
innate immune response (GO:0045087)  539  18  3.8x10‐5  0.0139  RPS6KA5, IFI27, TLR5, DUSP3, FCGR1B 
negative regulation of protein metabolic process (GO:0051248)  460  16  6.5x10‐5  0.0139  IGF2BP2, CIRBP, BANP, GCLC, DUSP3 
posttranscriptional regulation of gene expression (GO:0010608)  371  14  8.0x10‐5  0.0139  HNRNPA0, IGF2BP2, EIF1B, CIRBP, ASGR2 
response to arsenic‐containing substance (GO:0046685)  20  4  6.5x10‐5  0.0139  GCLC, GSTO1, FECH, DDX3X 
regulation of translational initiation by eIF2a ... (GO:0010998)  2  2  1.0x10‐4  0.0139  FECH, EIF2AK2 
regulation of eIF2 alpha phosphorylation by heme (GO:0010999)  2  2  1.0x10‐4  0.0139  FECH, EIF2AK2 
response to stress (GO:0006950)  2952  55  4.7x10‐5  0.0139  ALAS2, RPS6KA5, RAD23A, HNRNPA0, UBQLN1 
protoporphyrinogen IX metabolic process (GO:0046501)  11  3  2.0x10‐4  0.0167  FECH, ALAS2, EIF2AK2 
 
C=number of reference genes in the category; O=number of genes in the gene set and also in the category; rawP=p value from hypergeometric 
test; adjP=p value adjusted by the multiple test adjustment (Benjamini-Hochberg); Top Genes=top five genes from pathway based on meta-
analysis P-value 
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Figure Legend 
 
Figure 1. Gene transcripts associated with muscle strength in all participants 
 
A) Compares the individual meta-analyses performed in the Illumina-cohorts and the FHS 
separately. The dark grey points represent gene transcripts significantly associated with 
muscle strength (FDR<0.05). The light grey points were not significant in this analysis. The 
unfilled grey points were excluded due to significant heterogeneity (Cochran's Q-test p < 0.05 
(54)). The solid grey line shows the trend across all the genes.  
B) Shows the meta-analysis results by Manhattan plot. The dashed line indicates those 
probes significantly associated with grip strength after Benjamini-Hochberg correction, the 
solid line shows those significant after Bonferroni correction, for comparison. 
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Additional Files 
Table.Supplementary.1.Meta-analysis-results.all-participants.xlsx 
 Microsoft Excel file (.xlsx) 
 Significant meta-analysis results in analysis of all participants 
 
Table.Supplementary.2.Meta-analysis-results.younger-participants.xlsx 
 Microsoft Excel file (.xlsx) 
 Significant meta-analysis results in analysis of younger participants only 
 
Table.Supplementary.3.Meta-analysis-results.male-participants.xlsx 
 Microsoft Excel file (.xlsx) 
 Significant meta-analysis results in analysis of male participants only 
 
Table.Supplementary.4.Meta-analysis-results.female-participants.xlsx 
 Microsoft Excel file (.xlsx) 
 Significant meta-analysis results in analysis of female participants only 
 
Table.Supplementary.5.Additional-information-for-genes.xlsx 
 Microsoft Excel file (.xlsx) 
 Additional information for prominent genes 
 Tables 2 and 3 contain genes of particular robustness or interest that are here 
described in further detail 
 
Table.Supplementary.6.FHS-only-analysis-results.all-participants.xlsx 
 Microsoft Excel file (.xlsx) 
 Significant results for genes available in the FHS data only (all participants) 
 
Table.Supplementary.7.FHS-only-analysis-results.younger-participants.xlsx 
 Microsoft Excel file (.xlsx) 
 Significant results for genes available in the FHS data only (younger participants) 
 
Table.Supplementary.8.FHS-only-analysis-results.male-participants.xlsx 
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 Microsoft Excel file (.xlsx) 
 Significant results for genes available in the FHS data only (male participants) 
 
Table.Supplementary.9.WebGestalt-Gene-Ontology-pathway-analysis.xlsx 
 Microsoft Excel file (.xlsx) 
 Significantly enriched Gene Ontology terms in the 208 genes 
 WebGestalt-determined Gene Ontology terms that are significantly enriched in the 
208 genes found to be associated with muscle strength in the meta-analysis of all 
participants 
 
Table.Supplementary.10.WebGestalt-Phenotype-Ontology-pathway-analysis.xlsx 
 Microsoft Excel file (.xlsx) 
 Significantly enriched Human Phenotype Ontology terms in the 208 genes 
 WebGestalt-determined Human Phenotype Ontology terms that are significantly 
enriched in the 208 genes found to be associated with muscle strength in the meta-
analysis of all participants 
 
Table.Supplementary.11.network_GO-enrichment_results.xlsx 
 Microsoft Excel file (.xlsx) 
 Ontology enrichment results for the four clusters described in the network-analysis 
results section 
 For each network of co-expressed genes with >=10 genes in the network (n=4) we 
present the results of a Gene Ontology enrichment analysis. 
 
Table.Supplementary.12.Literature-search.xlsx 
 Microsoft Excel file (.xlsx) 
 Systematic search of the literature for 221 genes associated with muscle 
 For each of the 221 genes found in this analysis to be associated with muscle 
strength, GeneCards and PubMed were used to identify published research articles 
that contain both the gene ID (including part synonyms) and the word “muscle” 
 

